NBE Therapeutics
Dr. Anthony W. Tolcher, MD, is CEO, founder, and Director of Clinical Research at NEXT Oncology in San Antonio, Texas, a phase 1 program with the mission to accelerate the development of the next breakthrough cure for cancer through high-quality Phase 1 clinical and clinical pharmacology trials. In this function, Dr. Tolcher is coordinating and supervises clinical trials with novel targeted cancer therapies.
Dr. Tolcher is a board-certified Medical Oncologist with an MD degree from the University of British Columbia, Vancouver, Canada. Dr. Tolcher specialized in Internal Medicine and Medical Oncology in residency programs at the University of Toronto and again at the University of British Columbia, respectively, before engaging in oncology research at the National Cancer Institute (NCI), the National Institutes of Health (NIH) in Bethesda. He held a staff position at the British Columbia Cancer Agency in Vancouver before moving to the Institute for Drug Development, Cancer Therapy and Research Center University of Texas Health Science Center in San Antonio where he became Director of Clinical Research in 1999, a position he held for almost 10 years.
This person is not in the org chart
This person is not in any offices
NBE Therapeutics
1 followers
NBE-Therapeutics is developing best-in-class cancer therapies to increase survival and improve quality of life for cancer patients worldwide. The company’s next-generation immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate (ADC) platform. This best-in-class ADC platform creates highly potent and safe immune-stimulatory ADCs ("iADCs™") with an anthracycline payload, not only directly targeting tumor cells, but also inducing a long-lasting immunological anti-tumor effect. The company’s lead asset, NBE-002, an anti-ROR1 ADC, is due to start first-in-human clinical trials in three US centers by the end of 2020, focusing on triple negative breast cancer, but also other solid cancer indications which express ROR1. NBE-Therapeutics is a privately owned biotech company based in Basel, financed by Germany’s Boehringer Ingelheim Venture Fund, the Czech Republic’s PPF Group and Denmark’s Novo Holdings as international institutional investors, and by Swiss, German, and Dutch private investors. The company has raised over USD 65m, including a USD 22m Series C (2020), two USD 20m Series B rounds (2016 & 2018), a USD 3m Series A (2015), and over USD 4m from several non-dilutive grants from organizations including the Swiss Commission for Technology & Innovation, the European Commission, and Systems-X.